Immune reactivity during COVID-19: Implications for treatment

Area of Science:

• Immunology
• Hematology
• Infectious Diseases

Background:

• COVID-19 clinical symptoms range from fever and cough to severe acute respiratory distress syndrome (ARDS).
• Severe COVID-19 is associated with hematological changes like lymphopenia and eosinopenia, particularly in elderly patients with comorbidities.
• Elevated D-dimer, procalcitonin, and C-reactive protein (CRP) are prognostic biomarkers for coagulopathy in severe COVID-19.

Purpose of the Study:

• To review key hematological parameters with prognostic value in COVID-19.
• To summarize the immunological reactivity underlying COVID-19 pathogenesis.
• To highlight ongoing clinical trials targeting immune responses for COVID-19 therapy.

Main Methods:

• Review of clinical and laboratory findings in COVID-19 patients.
• Analysis of immunological responses, including T cell function and cytokine storm.
• Examination of therapeutic interventions and their outcomes.

Main Results:

• Severe COVID-19 involves lymphopenia, eosinopenia, and elevated inflammatory markers.
• Aberrant immune responses, or 'cytokine storm,' and distinct 'immunotypes' correlate with disease severity.
• Corticosteroids, anticoagulative therapy, and potentially IVIG/convalescent plasma show therapeutic promise, while tocilizumab has mixed results.

Conclusions:

• Hematological and immunological profiles are critical for predicting COVID-19 severity and outcomes.
• Targeting immune dysregulation is a key therapeutic strategy.
• Further clinical trials are needed to validate immunotherapies like IVIG and convalescent plasma.